Exelixis | EXEL - Vermögenswerte





Vermögenswerte Veränderung Datum
Acadia Pharmaceuticals USD 1.74B 137.67M 2026-06
Agios Pharmaceuticals USD 1.11B 76.57M 2026-06
Akebia Therapeutics USD 349.66M 12.86M 2026-06
Amgen USD 95.64B 3.14B 2026-06
AstraZeneca USD 115.83B 1.82B 2026-06
Bayer EUR 107.94B 3.4B 2026-03
BioMarin Pharmaceutical USD 8.59B 996.99M 2026-03
Bristol-Myers Squibb USD 87.63B 1.16B 2026-06
Cytokinetics USD 1.27B 151.06M 2026-03
Eisai JPY 1.56T 108.98B 2026-06
Eli Lilly USD 142.28B 25.71B 2026-06
Exelixis USD 2.59B 250.83M 2026-03
Genmab DKK 12.87B 5.85B 2025-12
Glaxosmithkline GBP 62.87B 19.47B 2026-03
Incyte USD 7.87B 533.53M 2026-06
Ionis Pharmaceuticals USD 2.99B 455.5M 2026-06
MacroGenics USD 217.87M 38.97M 2026-03
Merck USD 128.68B 8.18B 2026-03
Moderna USD 10.96B 527M 2026-06
Nektar Therapeutics USD 763.27M 482.86M 2026-03
Neurocrine Biosciences USD 5.36B 452.9M 2026-06
Novartis USD 122.03B 3.5B 2026-06
Pfizer USD 201.13B 6.49B 2026-06
Puma Biotechnology USD 202.86M 7.95M 2025-09
Sanofi EUR 128.02B 1.22B 2026-03
Takeda JPY 15.66T 210.16B 2026-06
Ultragenyx Pharmaceutical USD 1.26B 32M 2026-06
Xencor USD 724.96M 11.89M 2026-06